Christine Heyes
AstraZeneca (United Kingdom)(GB)
Research Areas
Bone Metabolism and Diseases, Natural product bioactivities and synthesis, Osteoarthritis Treatment and Mechanisms, Rheumatoid Arthritis Research and Therapies, Protease and Inhibitor Mechanisms
Most-Cited Works
- → (1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis(2012)39 cited
- → Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors(2012)22 cited
- → Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition(2012)5 cited
- (1<em>R</em>,2<em>R</em>)-<em>N</em>-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-<em>b</em>]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis(2012)